REVIVA PHARMACEUTICALS HOLDINGS, INC. 8-K — AI Bull & Bear Analysis

Reviva Pharmaceuticals' move from Nasdaq to the OTCQB Venture Market on May 14, 2026, marks a pivotal shift in the company's capital structure. While the company maintains its ticker symbol, the loss of a major exchange listing creates a stark divide between those who see this as a capitulation and those who view it as a necessary clearing event. The ultimate trajectory of the stock will now depend less on exchange compliance and almost entirely on the company's ability to deliver clinical success while navigating a significantly more restrictive funding environment.